RNA sequencing of the previously identified four-candidate biomarkers (TRIM43 (Tripartite Motif-Containing Protein 43), LEUTX (leucine 20 homeobox), PRAMEF2 (PRAME Family Member 2), KHDC1L (KH Domain Containing 1 Like)) [141] were performed in the MRI STIR positive muscle biopsy samples compared with the STIR negative control samples, and it was found that the expression of all these markers were elevated in 71% of FSHD samples [116]. The gene discussed is PRAMEF2; the disease is facioscapulohumeral muscular dystrophy.